Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
Status
Conditions
Treatments
Details and patient eligibility
About
This study examines tumor tissues and blood samples to aid in the development of therapies for brain cancer and other solid tumors. Studying samples of blood and tissue from patients with glioblastoma or other solid tumor in the laboratory may help doctors understand brain tumors and better inform future treatments.
Full description
PRIMARY OBJECTIVES:
I. Assessment of cell yield and percentage of viable cells upon tissue receipt at the cell processing facility.
II. Obtain discarded tumor tissue from surgical resections for further studies to aid in development of future therapies for glioblastoma (GBM) and other solid tumors.
SECONDARY OBJECTIVE:
I. Assessment of cell yield and percentage of viable cells from other solid tumor cells shipped to the cell processing facility.
EXPLORATORY OBJECTIVE:
I. An additional line of inquiry will be devoted to scientific exploration of the product's immunogenicity looking at important variables in the course of manufacture.
OUTLINE:
Patients undergo collection of tissue sample during surgery. Patients also undergo collection of blood sample.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Provide signed and dated informed consent form
- Any individual >= 18 years old
- Patients must have GBM or other solid tumor and undergoing surgery for diagnostic and therapeutic purposes
Exclusion criteria
- Individuals less than 18 years old
- Unable to understand and give consent
- Patients who are not surgical candidates
Trial design
141 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Kevin Judy, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal